Evaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experience

dc.authorid0000-0002-3203-741Xen_US
dc.contributor.authorBezirganoğlu, Handan
dc.contributor.authorOkur, Nilifer
dc.contributor.authorFeryal Taş, Funda
dc.contributor.authorÇelik, Kıymet
dc.contributor.authorÖzbek, Mehmet Nuri
dc.date.accessioned2023-10-25T11:52:19Z
dc.date.available2023-10-25T11:52:19Z
dc.date.issued2023en_US
dc.departmentMAÜ, Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractObjectives: To evaluate the clinical characteristics and treatment options of neonates requiring prolonged hospitalization due to persistent hyperinsulinemic hypoglycemia (HH). Methods: This retrospective cohort study included infants >34 weeks of gestation at birth who were born in our hospital between 2018 and 2021, diagnosed with HH, and required diazoxide within the first 28 days of life. The baseline clinical characteristics, age at the time of diagnosis and treatment options in diazoxide resistance cases were recorded. Genetic mutation analysis, if performed, was also included. Results: A total of 32 infants diagnosed with neonatal HH were followed up. Among the cohort, 25 infants were classified as having transient form of HH and seven infants were classified as having congenital hyperinsulinemic hypoglycemia (CHI). Thirty-one percent of the infants had no risk factors. The median birth weight was significantly higher in the CHI group, whereas no differences were found in other baseline characteristics. Patients diagnosed with CHI required higher glucose infusion rate, higher doses, and longer duration of diazoxide treatment than those in the transient HH group. Eight patients were resistant to diazoxide, and six of them required treatment with octreotide and finally sirolimus. Sirolimus prevented the need of pancreatectomy in five of six patients without causing major side effects. Homozygous mutations in the ABCC8 gene were found in four patients with CHI. Conclusions: The risk of persistent neonatal hyperinsulinism should be considered in hypoglycemic neonates particularly located in regions with high rates of consanguinity. Our study demonstrated sirolimus as an effective treatment option in avoiding pancreatectomy in severe cases.en_US
dc.identifier.citationHandan Bezirganoglu, Nilufer Okur, Kiymet Celik, Funda Feryal Tas & Mehmet Nuri Ozbek (2023) Evaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experience, The Journal of Maternal-Fetal & Neonatal Medicine, 36:2, 2272014, DOI: 10.1080/14767058.2023.2272014en_US
dc.identifier.doi10.1080/14767058.2023.2272014en_US
dc.identifier.issue2en_US
dc.identifier.pmid37860935en_US
dc.identifier.scopus2-s2.0-85174848836en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1080/14767058.2023.2272014
dc.identifier.urihttps://hdl.handle.net/20.500.12514/4291
dc.identifier.volume36en_US
dc.identifier.wosWOS:001087356800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÖzbek, Mehmet Nuri
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.relation.ispartofThe Journal of Maternal-Fetal & Neonatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectABCC8 mutationen_US
dc.subjectHyperinsulinemic hypoglycemiaen_US
dc.subjectDiazoxideen_US
dc.subjectNeonateen_US
dc.subjectSirolimusen_US
dc.titleEvaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
ozbek.pdf
Boyut:
1.46 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: